跳至主要内容

Pharmalego intermediates e-commerce platform launched; We have what scientific researchers are struggling to find

 1

E3 Ligase-CRBN、E3 Ligase-VHL、PROTAC linker……
Common building blocks in literature,
In reality, it's hard to find one!
Are you also searching for this?

PROTAC.webp

PROTAC Building Blocks

PharmlegoTM has developed more than 600 types of Linker and E3 ligase ligand building blocks, covering common long carbon chains, ethylene glycol long chains, spiroheterocyclic chains, CRBN, VHL, cIAP and MDM2 ligands and other chemical structures.

○E3 Ligase-CRBN>100
○E3 Ligase-VHL>100
○E3 Ligase-others >50
○PROTAC linker>1000
*If we cannot meet your needs, we can also customize it for you.

For more: https://cn.pharmalego.com/service/protac-custom.html


Sugar unit intermediates, base intermediates, delivery systems...
It is an intermediate that is obviously not difficult to synthesize.
But, it just takes a lot of time to synthesize!
Are you also doing this for 996 and 007?

Nucleic Acid Drugs.webp

Nucleic Acid Drugs

PharmalegoTM can efficiently and quickly provide customization and research and development services for monomers and delivery systems.  At present, we have more than 300 synthetic building blocks, which can modify and transform the ribose, base, and phosphate backbone of the monomers, as well as the delivery system, including the modification and transformation of GalNAc and LNP.

○Sugar modification>100 kinds of sugar unit intermediates
○Base modification>50 kinds of base intermediates
○Backbone modification, Rich experience in backbone modification chemistry
○Delivery system 1500+LNP, 30*GalNAc synthesis experience

*If we cannot meet your needs, we can also customize it for you.

For more:https://cn.pharmalego.com/service/oligonucleotides-custom.html

3
ADC linkers、Toxins、Payloads……
Even if there is an intermediate missing,
It’s like cooking without rice!
Are you also feeling helpless?

ADC.webp

ADC

PharmalegoTM has R&D laboratories and highly active drug production capabilities.  The scientific research team has professional and rich chemical modification technology and capabilities.  In-house toxins and linkers can meet customers' research and development needs from milligram to kilogram levels, and provide full-process services from drug development to preclinical CMC production.


300+ADC Linkers
50+ Toxins
30+ Payloads

Calendula: MMAE; MMAF
Maytansinoids: DM1; DM4
Pyrrobenzazepines and chlorobenzazepines: PBD
Camptothecins: DX; SD38

*If we cannot meet your needs, we can also customize it for you.

For more: https://cn.pharmalego.com/service/adc-custom.html

4
Benzene ring intermediates, pyridine intermediates, deuterated intermediates, pyrimidine intermediates...
Isn’t it time to use intermediates?
Research and development is difficult unless you have experienced it yourself!
Do you often start from scratch?

Intermediates

PharmalegoTM's pharmaceutical intermediate products cover a wide range of categories.  Including benzene ring intermediates, pyrimidine intermediates, pyridine intermediates and various heterocyclic intermediates, we provide clients with high-quality and high-purity intermediates to shorten the time to obtain target products and meet the different needs of clients.

Benzene Ring Intermediates, Aniline, Phenol, Benzaldehyde, Phenyl ether, phenylboronic acid, benzoyl, acetophenone, biphenyl...
Pyridine intermediates Aminopyridine Halopyridine Boric acid pyridine Hydroxypyridine Cyanopyridine Acylpyridine...
Deuterated Intermediates, Deuterated Anisole
Pyrimidine Intermediates, Aminopyrimidine, Arylamine Pyrimidine, Arylpyrimidine, Arylhydroxypyrimidine, Halopyrimidine, Hydroxypyrimidine...
Heterocyclic Intermediates, Benzopyrroles, Benzopyrans, Benzopyrazoles, Benzoxazines, Benzoxazoles...
Other, NA, Amino Acids, Naphthenes, Kinase Inhibitor, Spiro Ring, Bridge Ring, Alkynes, Alkylamine, Alkyl Acid, Alkenes...
*If we cannot meet your needs, we can also customize it for you.

For more:https://cn.pharmalego.com/service/intermediates-synthesis.html

5
High-End = Noble = High Price?
Are customized intermediates out of reach?
Fight for price, but also fight for quality?
Fight for purity, but also fight for safety?
Fight for buying, but also fight for customization?
Fight for after sales, but also fight for logistics?
Fight for research, but also fight for consultation?

PharmalegoTM Intermediate E-commerce Platform

Collection of synthetic biology technology service platform, analysis technology service platform, salt form and crystal form technology service platform, PROTAC R&D service platform, siRNA/ASO synthesis technology, ADC R&D service platform, electrochemistry technology service platform, photochemical technology service platform, continuous flow process technology service platform and other service platforms, Medicilon committed to cutting-edge, efficient, green and sustainable synthesis, from high-end intermediates to unique customization, and the entire process supports the research and development of new drugs.

Easy to Use, multiple compound search methods, logistics information can be traced
Multiple Guarantees, QA/QC quality control, guaranteed quality and guaranteed after-sales service
People-Oriented, multiple online consultation and feedback service channels
Flexible Form, online order purchasing, customization and synthesis

https://cn.pharmalego.com/
Everything you want is available here →

The birth of every new drug embodies the hard work and wisdom of countless scientific researchers.

From a one-stop biopharmaceutical preclinical R&D service platform, to Medicilon Academician Innovative Drug Maturation Center and New Drug Ecological Assistance Platform, to building a pharmaceutical network (PharmalegoTM), Medicilon is willing to help you overcome the obstacles on the journey of new drug research and development.  Medicilon let you forge ahead on the road of research and development, ride the wind and waves, and bravely climb to the pinnacle of innovation!

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati